Imre Kövesdi serves as Chief Executive Officer of VectorLogics, Inc. Prior to joining VectorLogics, he served as Chief Scientific Officer with GenVec Inc. (NASDAQ:GNVC). He joined GenVec in 1993 as one of its first employees and held several senior positions directing research, development and manufacturing before being appointed as CSO. Dr. Kovesdi was also a major contributor to GenVec's intellectual property portfolio. Prior to joining GenVec, he led projects in the development of gene expression systems and therapeutic gene design at the Medical Research Division of the New York-based American Cyanamid Company. He holds a PhD in molecular biology and a degree in electrical engineering. Dr. Kovesdi is the holder of over 80 US and foreign patents and has authored over 125 scientific articles in the areas of virology, gene delivery and molecular biology. Dr. Kovesdi has served on the boards of a number of biotechnology and information technology companies.

Balázs Sarkadi obtained his MD degree at Semmelweis Medical University, Budapest, Hungary, and his PhD in biochemistry at the Hungarian Academy of Sciences. He spent several years as a post-doc and then as visiting scientist at major universities in the United States and Canada. He is head of the Membrane Biology Research Group of the Hungarian Academy of Sciences and professor at Semmelweis University. He is member of the Hung. Acad. Sci. and of several international societies, past president of FEBS. The research of Balázs Sarkadi has been focused on the investigation of ABC membrane transporters, which play a major role in the multidrug resistance of cancer, in general pharmacology, and in stem cell function. He and his colleagues devised new diagnostic methods for the quantitative functional analysis of these ABC proteins, and developed compounds that modulate their function. Balazs Sarkadi has published more than 130 papers in international scientific journals. His current work is focusing on stem cell research, genetic modulation and differentiation of human embryonic stem cells, and generation of induced pluripotent stem cells. He is the Hungarian member of the Committee for Advanced Therapies at the European Medicines Agency (EMA).

Ferenc Uher, immunobiologist and stem cell expert, graduated in 1979 as a biologist from the Loránd Eötvös University of Sciences, Budapest, Hungary. Ferenc Uher is a Candidate Doctor of the Hungarian Academy of Sciences and habilitated professor at the Eötvös University. Between 1979 and 1996 he worked at the Immunology Department of the Eötvös University, where he concentrated his research on the autocrine regulation of B lymphocyte growth and differentiation, as well as on natural autoantibodies and the immunological homunculus. He spent the years 1983-86 as a visiting fellow scientist at the Immunology Branch of the NIH NCI. Between 1996 and 2002 he was a senior research fellow at the National Institute of Hematology and Immunology. Since 2002 he has been heading the Stem Cell Biology Unit of the Hungarian National Blood Transfusion Service (former National Medical Center), where his major research interest is the origin and biological functions of murine and human mesenchymal stem cells (MSCs) isolated from different tissues and organs. He is studying both the regenerative and immunosuppressive activity of MSCs in a variety of animal models of human disease, such as streptozotocin-induced diabetes and experimental autoimmune encephalomyelitis (EAE) in mice, mimicking human type-1 diabetes and multiple sclerosis, respectively. Ferenc Uher is the author or co-author of over 90 papers published in international scientific journals, and has participated in numerous collaborations over the years.